SCHEMBL24329677

SCHEMBL24329677

Cn1ccc(C(=O)Nc2nc(-c3ccccn3)cs2)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 6/20 0.67
▸ KDM4E B2RXH2 6/20 0.67
▸ ALDH1A1 P00352 5/20 0.67
▸ HTT P42858 5/20 0.67
▸ LMNA P02545 5/20 0.67
▸ KMT2A Q03164 4/20 0.67
▸ MEN1 O00255 3/20 0.67
▸ POLB P06746 3/20 0.67
▸ NPC1 O15118 1/20 0.67
▸ TP53 P04637 1/20 0.67
▸ HPGD P15428 1/20 0.67
▸ TSHR P16473 1/20 0.67
▸ MAPK1 P28482 1/20 0.67
▸ RAB9A P51151 1/20 0.67
▸ NPSR1 Q6W5P4 1/20 0.67
▸ HSD17B10 Q99714 1/20 0.67
▸ ADORA3 P0DMS8 7/20 0.65
▸ KDM4A O75164 1/20 0.65
▸ KDM4B O94953 1/20 0.65
▸ KDM5B Q9UGL1 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24329676 0.86 MAPT (0.53) L3MBTL1KDM4EALDH1A1HTTLMNA
SCHEMBL18997288 0.85 ADORA3 (0.82) L3MBTL1KDM4EALDH1A1HTTLMNA
SCHEMBL24330744 0.82 PARP1 (0.57) ALDH1A1HTTLMNAKMT2AMEN1
SCHEMBL26884220 0.82 SMN1; SMN2 (0.48) L3MBTL1KDM4EALDH1A1HTTLMNA
SCHEMBL26884178 0.82 KMT2A (0.47) L3MBTL1KDM4EALDH1A1HTTLMNA
SCHEMBL26658235 0.79 LMNA (0.59) KDM4EALDH1A1HTTLMNAKMT2A
SCHEMBL26884172 0.78 MEN1 (0.54) KDM4EALDH1A1HTTLMNAKMT2A
SCHEMBL26884180 0.78 KMT2A (0.61) ALDH1A1HTTLMNAKMT2AMEN1
SCHEMBL17716927 0.78 ALDH1A1 (0.75) L3MBTL1KDM4EALDH1A1HTTLMNA
SCHEMBL18997291 0.77 L3MBTL1 (0.67) L3MBTL1KDM4EALDH1A1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
WO-2022082071-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF US THEREOF CARTHRONIX, INC. (US) 2022-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF STAT1, STAT3, STAT6 L3MBTL1 4645/4885KDM4E 4225/4885ALDH1A1 3368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback